Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 19Neoplasm Metastasis 5Triple Negative Breast Neoplasms 3Brain Neoplasms 3Stomach Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2HER2-positive Breast Cancer 2Urinary Bladder Neoplasms 1Thrombocytosis 1Solid Tumor 1Recurrence 1Rare Tumour 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Ovarian Neoplasms 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Meningioma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

Radiotherapy 4Carboplatin 4Trastuzumab 3Fulvestrant 3Cyclophosphamide 3Chemotherapy, Adjuvant 3Paclitaxel 2Magnetic Resonance Spectroscopy 2Letrozole 2Docetaxel 2repotrectinib 1proto-oncogene protein c-fes-fps 1palbociclib 1neratinib 1gallium 68 PSMA-11 1fluciclovine F-18 1entrectinib 1Zolpidem 1Vorinostat 1Vinorelbine 1Venlafaxine Hydrochloride 1Thiotepa 1Taxes 1Tamoxifen 1Sugars 1Sampling Studies 1Reverse Transcriptase Polymerase Chain Reaction 1Radiotherapy, Conformal 1Radiotherapy, Adjuvant 1Radiosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Lobular × neratinib × Clear all
NCT05919108 2025-09-09

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Vanderbilt-Ingram Cancer Center

Phase 2 Recruiting
30 enrolled

Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡